🔬 Latest pharma industry updates 👇
🏗️ Novartis looking to invest $23B in new U.S. facilities, company says tariffs not primary motivation despite significant business impact.
⚠️ Biotech executives urge Congress to reverse FDA layoffs, warning cuts threaten drug approvals.
📉 Novavax shares plunged 22% after FDA delays COVID vaccine decision.
🌐 Trump pauses most global tariffs (90 days) but raises duties on China imports to 145%.
📊 China faces obesity epidemic; 65% overweight by 2030 (~630M), potentially straining healthcare.
🏭 Novo Nordisk investing €1B in Brazil, expanding GLP-1 injectable drug manufacturing.
🔴 A 2nd child died from measles in Texas, the child was not vaccinated and had no known health issues.
⚖️ Judge blocked NIH’s controversial 15% indirect research cost cap, calling it unlawful and arbitrary.
💰 Merida Biosciences launches with $121M Series A funding, developing precision therapeutics targeting pathogenic antibodies for autoimmune and allergic diseases.
📊 Boehringer Ingelheim achieved €26.8B revenue (+6.1%), driven by Jardiance® and Ofev®. Jardiance®.
🧠 A brain-computer interface allowed a stroke survivor mute for 18 years to communicate via neural activity-to-speech translation.
🧬 Rhythm Pharmaceuticals Inc. Imcivree succeeded in Phase 3 trials for obesity linked to brain injury, helping patients lose ~16% body weight.
🤝 GSK licensed South Korea’s ABL Bio Inc. technology for blood-brain barrier drug delivery, targeting neurodegenerative diseases.
🚫 Trump administration refused Medicare coverage expansion for obesity drugs like Wegovy® and Zepbound.
🏆 KBI Biopharma named top global biologics CDMO at the 2025 Leadership Awards.
💷 London to invest up to £600M creating a unified healthcare data research service, streamlining clinical trials.
⚖️ Mylan (Viatris) to pay $335M in U.S. opioid crisis settlement, accused of misleading marketing contributing to widespread opioid misuse.
📈 ZyVersa Therapeutics Inc. Therapeutics shares surged 109% after highlighting accelerated regulatory path for VAR 200, treating kidney diseases.
⚖️ Jazz Pharmaceuticals to pay $145M antitrust settlement over allegations of delaying generic narcolepsy drug versions.
❌ Rallybio halted FNAIT drug candidate RLYB212 after failed Phase 2 trial, shares plunge; shifts focus to alternative candidate RLYB116.
💔 Tango Therapeutics cuts 20% staff trimming preclinical programs due to financial constraints.
🟢 FDA approved Bristol Myers Squibb’s Opdivo-Yervoy combination for aggressive colorectal cancer.
📉 Tempest Therapeutics seeking buyer/partner amid cash crunch; promising liver cancer drug amezalpat ready for Phase 3 but lacks sufficient funding.
🐁 FDA announces roadmap to phase out animal drug testing, promoting human-relevant alternatives (AI models, organ-on-a-chip systems).